The biopharmaceutical contract manufacturing market is projected to grow at a CAGR of 10% during 2022-2035, claims Roots Analysis

With the advent of novel technologies and rising preference for such therapeutic interventions, biologics have made a significant impact in the pharmaceutical domain, delivering a ground-breaking treatment regimen for a myriad of disease indications.

London
Roots Analysis has announced the addition of the “Biopharmaceutical Contract Manufacturing Market, 2022–2035” report to its list of offerings.

In pursuit of both time and cost savings, as well as to access higher scales of production, outsourcing has emerged as a lucrative option for biologic drug developers. Driven by several blockbuster products, a burgeoning pipeline of biologic drugs, the demand for reliable contract service providers, which have the required expertise and advanced manufacturing capabilities, is expected to grow at a commendable pace in the coming years. Currently over 275 companies claim to be biopharma CDMO / biopharma CMO, in compliance with the regulatory standards. It is also worth highlighting that biopharmaceutical contract manufacturers are actively trying to consolidate their presence in this field by entering into strategic alliances in order to meet the indubitably rising demand for biologics. In 2021, a sum of over USD 70 billion was invested in the cell and gene therapy domain. However, biologics manufacturing is fraught with various challenges.

To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/reports/250/request-sample.html

Key Market Insights

Presently, more than 275 players offer contract manufacturing services for biologics
This segment of the industry is dominated by the presence of mid-sized players (51-200 employees) and start-ups / small players (2-50 employees), which collectively represent more than 80% of the total contract manufacturers. In addition, it is important to mention that about 33% of the firms were founded post 2010.

Approximately 60% of the players carry out manufacturing operations across all scales of operation
More than 60% of the service providers are engaged in manufacturing of recombinant proteins and peptides. This was followed by 49% CMOs that claim to have the required capabilities to provide antibody manufacturing services. It is worth mentioning that a number of biologic manufacturers in this domain have the required capabilities to provide manufacturing services for niche and upcoming classes of biologics, such as ADCs, cell therapies, gene therapies and plasmid DNA.

450+ manufacturing facilities dedicated to biologic-based therapies have been established globally
North America has emerged as a key manufacturing hub for biotherapeutics, featuring the presence of nearly 33% of the total manufacturing facilities. This is followed by facilities located in Europe and Asia-Pacific. Prominent manufacturing hubs within Europe include (in decreasing order of number of facilities) Germany, the UK, France, Italy and Spain.

800 partnerships were established in this domain, during the period 2015-2022
Partnership activity of biologic contract manufacturers has increased at a CAGR of 42%, during the given period. Manufacturing agreements emerged as the most popular type of partnership model adopted by industry stakeholders (37%), followed by product development and manufacturing agreements (19%). Further, over 80% of the expansion projects undertaken by industry stakeholders were initiated since 2020.

Currently, 54% of the overall, installed biopharmaceutical contract manufacturing capacity is for mammalian expression systems
The maximum (49%) capacity is installed with players companies based in Asia-Pacific. It is worth mentioning that the aforementioned region has a higher number of players engaged in biopharmaceutical contract manufacturing, which have further established multiple production facilities. This is followed by the capacity available with players having headquarters in North America (25%) and Europe (24%).

For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html

You may also be interested in the following titles:
1. Peptide Therapeutics: Contract API Manufacturing Market: Industry Trends and Global Forecasts, 2022-2035
2. Biopharmaceutical Excipient Manufacturing Market: Industry Trends and Global Forecasts, 2022-2035




Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

 

comments (0)

81 more from jameshebrew